COMPANY INFO
Junevity is a biotechnology company founded in 2023 at UCSF. The founders are John Hoekman, Janine Sengstack, Rob Cahill, and Hao Li. The company has 13 employees and is headquartered in San Francisco, CA. Junevity operates in the Biotechnology industry and develops cell reset therapeutics aimed at extending healthspan and lifespan by reversing diseases of aging through novel transcription factor medicines using large-scale human data and artificial intelligence. (junevity.com, pitchbook.com)
Junevity is a biotechnology company founded in 2023 and headquartered in San Francisco, CA. With a team of 13 employees, Junevity focuses on developing cell reset therapeutics to extend healthspan and lifespan by reversing diseases associated with aging. The company leverages large-scale human data and artificial intelligence to identify novel transcription factor medicines that can target and reverse cellular damage. Founded at UCSF by John Hoekman, Janine Sengstack, Rob Cahill, and Hao Li, Junevity operates at the intersection of biotechnology, longevity, and next-generation therapeutics.
Junevity funding has made headlines due to their innovative approach and strong scientific foundation. Since its inception, Junevity has raised a total of $10 million, all from a single Seed round that closed on February 13, 2025. This initial injection of capital marks a foundational milestone in the company’s journey, allowing it to execute on key research and development goals for its RESET platform and pipeline. Junevity’s investment strategy is focused on leveraging this substantial seed capital to demonstrate proof-of-concept for its transcription factor-based siRNA therapeutics, targeting high-impact diseases such as Type 2 diabetes, obesity, and frailty. The company’s funding rounds and investor support are poised to accelerate advancement toward clinical applications, further attracting significant attention in the biotechnology venture capital landscape.
This Seed funding round aimed to enhance Junevity's RESET platform and develop the company's first therapeutic candidates addressing Type 2 diabetes, obesity, and frailty. The capital is powering research and preclinical development on siRNA therapeutics targeting key transcription factors, with a goal of extending both healthspan and lifespan.
Goldcrest Capital was a lead investor in Junevity’s Seed round. As a venture capital firm focused on early-stage startups in transformative technology and biotech, Goldcrest brings not only financial support to Junevity but also strategic guidance and deep industry experience. Their investment signals strong confidence in Junevity's science and growth potential.
Godfrey Capital also led the Seed investment round for Junevity funding. With a background in biotech and health innovation investing, Godfrey Capital plays a critical role in scaling Junevity’s operations and supporting the translation of research breakthroughs into clinical and commercial success.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Junevity funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.